0000000001044182

AUTHOR

Kirsten Müller-vahl

showing 1 related works from this author

The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols i…

2020

Background: Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterized by motor and vocal tics. First-line treatments for tics are antipsychotics and tic-specific behavioral therapies. However, due to a lack of trained therapists and adverse events of antipsychotic medication many patients seek alternative treatment options including cannabis. Based on the favorable results obtained from case studies on different cannabis-based medicines as well as two small randomized controlled trials using delta-9-tetrahydrocannabinol (THC), we hypothesize that the cannabis extract nabiximols can be regarded as a promising new and safe treatment strategy in TS.Objective: To …

tourette syndromemedicine.medical_specialtyTHCTicslcsh:RC435-571NabiximolsPlacebo-controlled studynabiximolsPlaceboTourette syndromelaw.inventionStudy Protocol03 medical and health sciencescannabidioltetrahydrocannabinolcannabinoids0302 clinical medicineRandomized controlled triallawInternal medicinelcsh:Psychiatrymental disordersmedicinechronic tic disorderPsychiatrybusiness.industryticsnabiximols ; tetrahydrocannabinol ; cannabidiol ; chronic tic disorder ; tourette syndrome ; THC ; tics ; Tourette-Syndrom ; cannabinoidsmedicine.disease030227 psychiatryClinical trialPsychiatry and Mental healthChronic Tic Disorderbusiness030217 neurology & neurosurgerymedicine.drugFrontiers in Psychiatry
researchProduct